Medicover AB (publ)
Medicover AB (publ) Fundamental Analysis
Medicover AB (publ) (MCVEY) shows moderate financial fundamentals with a PE ratio of 32.49, profit margin of 2.84%, and ROE of 13.64%. The company generates $2.3B in annual revenue with strong year-over-year growth of 19.78%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 40.6/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze MCVEY's fundamental strength across five key dimensions:
Efficiency Score
WeakMCVEY struggles to generate sufficient returns from assets.
Valuation Score
ModerateMCVEY shows balanced valuation metrics.
Growth Score
ModerateMCVEY shows steady but slowing expansion.
Financial Health Score
WeakMCVEY carries high financial risk with limited liquidity.
Profitability Score
WeakMCVEY struggles to sustain strong margins.
Key Financial Metrics
Is MCVEY Expensive or Cheap?
P/E Ratio
MCVEY trades at 32.49 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, MCVEY's PEG of 0.38 indicates potential undervaluation.
Price to Book
The market values Medicover AB (publ) at 4.06 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 2.26 times EBITDA. This is generally considered low.
How Well Does MCVEY Make Money?
Net Profit Margin
For every $100 in sales, Medicover AB (publ) keeps $2.84 as profit after all expenses.
Operating Margin
Core operations generate 5.81 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $13.64 in profit for every $100 of shareholder equity.
ROA
Medicover AB (publ) generates $2.75 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Medicover AB (publ) produces operating cash flow of $308.54M, showing steady but balanced cash generation.
Free Cash Flow
Medicover AB (publ) produces free cash flow of $156.31M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $1.04 in free cash annually.
FCF Yield
MCVEY converts 7.26% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
32.49
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.38
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.06
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.92
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
2.70
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.70
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.14
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.08
vs 25 benchmark
How MCVEY Stacks Against Its Sector Peers
| Metric | MCVEY Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 32.49 | 27.91 | Worse (Expensive) |
| ROE | 13.64% | 687.00% | Weak |
| Net Margin | 2.84% | -45285.00% (disorted) | Weak |
| Debt/Equity | 2.70 | 0.33 | Weak (High Leverage) |
| Current Ratio | 0.70 | 2795.76 | Weak Liquidity |
| ROA | 2.75% | -13557.00% (disorted) | Weak |
MCVEY outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Medicover AB (publ)'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
120.00%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-34.08%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
166.42%
Industry Style: Defensive, Growth, Innovation
High Growth